Eyegate Pharmaceuticals Inc EYEG shares are trading higher by 116% at $6.74 Tuesday morning after the company announced it entered a non-binding letter of intent to acquire Bayon Therapeutics for roughly $7.1 million.
Eyegate Pharmaceuticals is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. The company's lead product EGP-437 incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through a proprietary drug delivery system, the EyeGate II Delivery System.
Eyegate Pharmaceuticals has a 52-week high of $8.18 and a 52-week low of $3.10.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
